Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of WILFACTIN in children under 6 years with von Willebrand disease
2004-005051-34Phase 3Completed
- Sponsor
- LFB Group
- Start
- May 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of von Willebrand factor human in von Willebrand disease (VWD), sponsored by LFB Group. Primary endpoint: Biological efficacy: VWF recovery. Started May 2007; status: completed.
02
Drugs
von Willebrand factor human
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2004-005051-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005051-34.